Successful dabrafenib and trametinib combination therapy in a patient with recurrent BRAF V600E -mutant non-small-cell lung cancer and coexisting radiation pneumonitis.
Eriko NakamuraMasahide OtaRyosuke MatsudaMaiko TakedaTomomi FujiiYoshifumi YamamotoShigeto HontsuMotoo YamauchiMasanori YoshikawaShigeo MuroPublished in: Respirology case reports (2024)
There have been several reports of drug-induced lung injury caused by molecular-targeted agents. Additionally, medical history of interstitial lung disease and chest irradiation are established risk factors for the development and progression of drug-induced lung injury. Moreover, the presence of fibrosis on chest computed tomography before treatment is a predictive factor for the appearance of pneumonia induced by anticancer drugs. Accordingly, patients with a history of interstitial lung disease or pneumonitis were excluded from clinical trials of dabrafenib and trametinib combination therapy for patients with previously treated BRAF V600E -mutant metastatic non-small-cell lung cancer. This article presents a case of successful dabrafenib and trametinib combination therapy in a patient with BRAF V600E -mutant non-small-cell lung cancer who had a history of radiation pneumonitis and developed recurrence after conventional chemoradiotherapy.
Keyphrases
- interstitial lung disease
- combination therapy
- drug induced
- wild type
- liver injury
- systemic sclerosis
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- computed tomography
- clinical trial
- adverse drug
- case report
- metastatic colorectal cancer
- squamous cell carcinoma
- radiation induced
- healthcare
- small cell lung cancer
- positron emission tomography
- magnetic resonance imaging
- cancer therapy
- locally advanced
- drug delivery
- randomized controlled trial
- open label
- newly diagnosed
- phase ii
- electronic health record
- respiratory failure